The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Stocks•13 April 2026•

1 min read

Legal Investigations Launched into Orthofix and Humacyte Over Governance and Regulatory Delays

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1Law firm Kahn Swick & Foti has launched an investigation into Orthofix Medical (OFIX) following the termination of its top executives.

2Humacyte (HUMA) officers are under investigation after the company announced the FDA requires more time to review its Biologic License Application.

Law firm Kahn Swick & Foti (KSF) has initiated formal investigations into the leadership of Orthofix Medical and Humacyte. The probe into Orthofix follows the abrupt termination of the company's CEO, CFO, and Chief Legal Officer for cause. Simultaneously, Humacyte faces scrutiny after disclosing that the U.S. Food and Drug Administration (FDA) requires additional time to review its Biologic License Application (BLA). KSF is evaluating whether the officers and directors of these companies breached their fiduciary duties or violated federal securities laws. These developments have introduced significant uncertainty regarding corporate governance and regulatory timelines for both firms. While such investigations are common precursors to class-action lawsuits, they often exert downward pressure on investor sentiment.